The abstract is read at the publisher; the summary is JClub's.
In lipopolysaccharide-primed human monocyte-derived microglia and human brain slices, the P2X7R agonist BzATP drives concentration-dependent IL-1β and IL-18 release that is blocked by selective P2X7R antagonists.
- Why it matters: Traumatic brain injury lacks approved treatments, and microglial activation and neuroinflammation after injury create a therapeutic window for targeting key inflammatory pathways.
- What they did: The study used in vitro primed human monocyte-derived microglia and ex vivo human brain tissue slices, testing clinical-stage brain-penetrant P2X7R antagonists against BzATP-evoked cytokine release.
- The result: P2X7R antagonists suppressed BzATP-induced pro-inflammatory cytokine release in both models, and NLRP3 or caspase-1 inhibition also reduced it, supporting inflammasome involvement and translational relevance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.